Clinical trialHuman

Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy

Endocrine, 2001 Feb. Broglio F, Benso A, Valetto MR and 7 others.

Study type

Clinical trial

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Endocrine

Published

2001 Feb

PubMed

PMID 11322491 ↗

DOI

10.1385/ENDO:14:1:105 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Hexarelin →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AdultBlood PressureCardiomyopathy, DilatedCardiomyopathy, HypertrophicGrowth HormoneHeartHeart RateHormonesHumansMyocardiumOligopeptidesRadionuclide Imaging

Other papers on Hexarelin

Randomized controlled trial · 1999

Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans

Clinical trial · 1999

The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin

Review · 2014

The cardiovascular action of hexarelin

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page